SPOTLIGHT: Argos, J&J make a deal

Therakos, a Johnson & Johnson company, has struck a licensing deal with Argos Therapeutics. Therakos gains Arros' technology related to part of the immune system known as regulatory T cells. Financial details were not disclosed. Release

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.